Side-by-side · Research reference

CJC-1295 (no DAC)vsGDF-8

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 1HUMAN-REVIEWED15/51 cited

BAnimal-StrongHUMAN-REVIEWED23/48 cited

CJC-1295 (no DAC)

Short-acting GHRH · No DAC variant

100 mcgPer doseTeichman 2006

~30 minHalf-lifeIonescu 2006

Phase 1Evidence levelTeichman 2006 Sigalos 2018

SQ · Pre-sleep · 1–2×/day

GDF-8

TGF-β Superfamily · Negative Muscle Regulator

15–20%Muscle mass gain (MSTN−/−)

↓ AdiposityFat reduction (loss-of-function)Herman 2026 Jacquez 2026

No adversePhenotype (genetic null)Jacquez 2026

Not administered — research target for inhibition

01Mechanism of Action

Parameter

CJC-1295 (no DAC)

GDF-8

Primary target

Pituitary GHRH receptorTeichman 2006

Activin type II receptors (ActRIIA/B) on skeletal muscleIglesias 2026

Pathway

GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisTeichman 2006

MSTN → ActRII/TGFBR1 → Smad2/3 signaling → muscle protein synthesis suppression

Downstream effect

Pulsatile GH release matching physiological pattern; subsequent IGF-1 elevationIonescu 2006

Restricts muscle hypertrophy, limits satellite cell activation, increases proteolysis via ubiquitin-proteasome and autophagy pathwaysGong 2026 Iglesias 2026

Feedback intact?

Yes — short pulse preserves somatostatin negative feedbackIonescu 2006

Yes — part of muscle-pituitary endocrine axis; muscle-derived MSTN influences FSH synthesisIglesias 2026

Origin

Modified human GRF 1-29 with four substitutions (D-Ala²/Gln⁸/Ala¹⁵/Leu²⁷) for protease resistanceTeichman 2006

Endogenous myokine secreted by skeletal muscle; circulates systemically as latent complexIglesias 2026

Antibody development

Not reported in short-term studies

—

02Dosage Protocols

Parameter

CJC-1295 (no DAC)

GDF-8

Standard dose

100 mcg per injectionTeichman 2006

Often paired with ipamorelin in same syringe.

—

Frequency

1–2× daily (pre-sleep ± morning)

—

Lower / starter dose

50 mcg per dose

—

Evidence basis

Phase 1 (CJC-1295 with DAC); analog dataTeichman 2006 Ionescu 2006

No-DAC variant is less studied directly; PK extrapolated from native GHRH.

—

Duration

8–12 weeks on / 4 off (anecdotal)

—

Reconstitution

Bacteriostatic water

—

Timing

Pre-sleep + fasted preferred

—

Half-life

~30 minIonescu 2006

Short pulse vs CJC-1295-DAC (~8 days). Choose no-DAC for pulsatile, DAC for sustained.

—

Clinical use

—

None — MSTN is a research target for inhibition, not a therapeutic peptide administered to humans

Sold by research suppliers (e.g., CertaPeptides) for in vitro / animal studies only.

Inhibition strategies

—

Monoclonal antibodies, VLP-based active immunotherapy, gene editing (CRISPR)

VLP immunogen (MS2.87-97)

—

Active immunization protocol in mice — elicits anti-MSTN antibodies without GDF11 cross-reactivityJacquez 2026

Reduces body fat, increases muscle mass and grip strength; no major safety concerns in animal models.Jacquez 2026

Dual immunization (MSTN + Activin A)

—

Combined active immunization in GH-deficient miceMansoor 2026

Improves skeletal muscle performance beyond single-target inhibition.Mansoor 2026

Gene editing outcomes

—

Precision CRISPR edits produce double-muscle phenotype, improved carcass quality in livestock

Pleiotropic effects on metabolism, reproduction, and welfare require systematic evaluation.

03Metabolic / Fat Loss Evidence

Parameter

CJC-1295 (no DAC)

GDF-8

Primary mechanism

—

MSTN loss-of-function reduces fat accumulation independent of muscle mass effects

Human genetic evidence

—

Humans with MSTN function-disrupting variants have increased muscle mass, strength, and reduced adiposityHerman 2026

Animal model outcomes

—

VLP-immunized mice: reduced age-associated weight gain, significantly lower body fat by DEXAJacquez 2026

Adipose-muscle crosstalk

—

MSTN modulates myostatin-TAZ signaling; inhibition shifts adipose expansion toward hyperplasiaLi 2026

Metabolic benefits

—

Improved metabolic health in genetic MSTN null modelsJacquez 2026

Age-related effects

—

MSTN upregulation linked to age-dependent muscle atrophy and fat accumulation

04Side Effects & Safety

Parameter

CJC-1295 (no DAC)

GDF-8

Injection site reaction

Erythema, mild pruritus

—

Flushing / headache

Common transient effect

—

Cortisol elevation

Minimal at standard doses

—

Prolactin elevation

Minimal

—

Glucose intolerance

Possible at high cumulative doses

—

IGF-1 elevation

Dose-dependent; monitor with chronic use

—

Cancer risk

Contraindicated in active malignancy (GH/IGF-1 axis)

—

Pregnancy / OB

Avoid

—

Genetic null phenotype

—

No known adverse phenotypes in humans or mice with MSTN loss-of-functionJacquez 2026

Antibody cross-reactivity risk

—

Non-selective inhibitors may block GDF11, affecting cardiac and neural function

VLP immunotherapy safety

—

No major safety concerns in mice; rare hypersensitivity possibleJacquez 2026

Echocardiography

—

No cardiac abnormalities detected in MSTN-immunized miceJacquez 2026

Pleiotropic effects (gene editing)

—

MSTN editing may affect reproductive performance, metabolic homeostasis, and animal welfare

Assay variability

—

Circulating MSTN levels often fail to mirror intramuscular changes; clinical interpretation challengingIglesias 2026

Absolute Contraindications

CJC-1295 (no DAC)

·Active malignancy or cancer history
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

GDF-8

·Not applicable — MSTN is not administered as a therapeutic agent

Relative Contraindications

CJC-1295 (no DAC)

·Untreated diabetes
·Severe insulin resistance

GDF-8

·Inhibition strategies contraindicated in conditions requiring maintained muscle proteostasis (theoretical)

05Administration Protocol

Parameter

CJC-1295 (no DAC)

GDF-8

1. Reconstitution

Add 2 mL bacteriostatic water to 2 mg vial → 1 mg/mL = 100 mcg per 0.1 mL. Roll gently.

GDF-8 (myostatin) is not administered to humans. It is studied as a target for inhibition using monoclonal antibodies, active immunotherapy (VLP-based vaccines), or gene editing (CRISPR). Research-grade peptide supplied by vendors like CertaPeptides is intended for in vitro and animal studies only.

2. Injection site

Subcutaneous, abdomen or thigh. Rotate sites.

Clinical development focuses on blocking MSTN activity via: (1) neutralizing monoclonal antibodies targeting mature MSTN or ActRII receptors; (2) active immunotherapy generating endogenous anti-MSTN antibodies (e.g., MS2.87-97 VLP platform); (3) precision gene editing to disrupt MSTN expression in livestock or therapeutic contexts.

3. Timing

Pre-sleep preferred. Often combined with ipamorelin in the same syringe.

MS2.87-97 VLP administered to mice elicits anti-MSTN antibodies targeting a discrete epitope in mature MSTN protein. Immunization schedule and dose optimized for sustained antibody response without GDF11 cross-reactivity. No human protocols established.Jacquez 2026

4. Storage

Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.

CRISPR-mediated MSTN knockout produces double-muscle phenotype in livestock (cattle, swine, sheep). Ethical frameworks and welfare assessments required; pleiotropic effects on reproduction, metabolism, and health must be systematically evaluated before human translation.

5. Needle

29–31G, 4–8 mm insulin syringe.

—

06Stack Synergy

CJC-1295 (no DAC)

+ Ipamorelin

Strong

View Ipamorelin →

CJC-1295 (no DAC) and ipamorelin are the canonical "GHRH + GHRP" dual-axis stack at physiological timing. Both peak within 30 min and clear within 2 hours, producing a sharp, high-amplitude GH pulse closely resembling natural physiology. Preferred over the CJC-1295-DAC + ipamorelin stack when pulsatility (vs sustained elevation) is the goal.

CJC-1295 (no DAC): 100 mcg SQ · pre-sleep
Ipamorelin: 200–300 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation, recovery, body composition

Teichman 2006 Raun 1998

GDF-8

— no documented stacks